2.2.1. Safety Variables
ADVERSE EVENTS
Regarding safety measures, all patients were discharged 4 h post-implantation. Throughout the treatment phase and up to the 6-month follow-up, there were no reported adverse events (AEs) or serious adverse events (SAEs) linked to the procedure. Peripheral blood tests were conducted at intervals of 1 week and at 1, 3, and 6 months after the intervention. The results from these tests showed no notable anomalies, further affirming the procedure’s safety.